The drivers of metastasis in certain cancers include genes and pathways that are mechanistically independent of the oncogenic tumorinitiating mutations [1] [2] [3] [4] . In other cancers, however, the pathways driving carcinoma formation additionally mediate metastasis. One example of this alternative paradigm is ccRCC, a tumor type in which the VHL-HIF pathway mediates both tumor initiation and metastasis 5, 6 .
The drivers of metastasis in certain cancers include genes and pathways that are mechanistically independent of the oncogenic tumorinitiating mutations [1] [2] [3] [4] . In other cancers, however, the pathways driving carcinoma formation additionally mediate metastasis. One example of this alternative paradigm is ccRCC, a tumor type in which the VHL-HIF pathway mediates both tumor initiation and metastasis 5, 6 .
VHL is a classical gatekeeper inhibiting renal tumor initiation [7] [8] [9] [10] [11] [12] [13] . The main tumor-suppressive function of VHL is its role in mediating the degradation of HIF2-α (also known as endothelial PAS domain protein 1, EPAS1), a transcription factor that drives the expression of multiple target genes with tumorigenic functions 5, [14] [15] [16] . Additionally, at least one HIF2-α target gene, CXCR4, is a direct mediator of metastatic colonization 1, 6, 17, 18 . Therefore, it was previously suggested that loss of VHL might directly lead to metastatic tumor phenotypes through HIF activation 6 . This model, however, is challenged by the clinical findings that most VHL-negative ccRCCs never metastasize 19 and that VHL mutation status does not correlate with poor disease outcome 20, 21 , even though CXCR4 expression does 6, 22 .
We used the combined power of new experimental model systems and large clinical datasets to test the hypothesis that the activation of CXCR4 and other metastatic genes downstream of VHL-HIF is enabled by epigenetic events in metastatic subpopulations of renal cancer cells.
RESULTS ccRCC metastasis model with clinically relevant correlates
We isolated metastatic subpopulations of the VHL-deficient ccRCC cell line 786-O, which was originally derived from a primary tumor of an individual with widely metastatic disease ( Supplementary  Fig. 1a ) 23 . The parental cell line contained rare clones that, by intravenous inoculation into mice, were capable of forming rapidly growing metastases in the lungs, the most frequent site of ccRCC metastasis 19 ( Supplementary Fig. 1b) . Isolation of cells from these lesions yielded variants (786-M1A and 786-M1B) that were ~100-fold enriched for lung-colonizing activity ( Fig. 1a and Supplementary  Fig. 1c,d ). Second-generation derivatives (786-M2A and 786-M2B) recapitulated the behavior of the 786-M1-generation cells ( Fig. 1a and Supplementary Fig. 1c,d) . The enhanced metastatic phenotype was not associated with changes in cell proliferation in vitro (Supplementary Fig. 1e ). The 786-M1A derivatives were also more metastatic to the lung when inoculated into the orthotopic site (Fig. 1b) . Orthotopic tumors formed by 786-O cells had high-grade ccRCC histology with prominent epithelioid features, whereas the metastatic 786-M1A cells showed areas of epithelioid ccRCC and also areas of sarcomatoid features ( Fig. 1c and Supplementary Fig. 1f ). Lung metastatic nodules presented only sarcomatoid histology ( Fig. 1c and Supplementary Fig. 1f) . When compared to the parental cells, all the metastatic cells tested were more aggressive in forming osteolytic bone metastasis (Fig. 1d,e and Supplementary Fig. 2a,b ) and invasive lesions in the brain (Fig. 1f,g and Supplementary  Fig. 2c ), organs commonly affected by ccRCC 19, 24 .
We used genome-wide transcriptional profiling to identify 155 genes associated with this metastatic phenotype (Supplementary Table 1 ). In an unsupervised hierarchical clustering analysis of three independent human datasets comprising 758 samples (The Cancer Genome Atlas (TCGA) cohort and the datasets deposited in the Gene Expression Omnibus (GEO) under accessions GSE2109 and GSE3538 (ref. 25) ), this 155-gene set was able to identify tumor subgroups that had an expression profile resembling that of the metastatic cells ( Supplementary Fig. 3a-c) . These datasets were derived from surgically removed untreated primary ccRCCs, with the exception of three tumors in the GSE2109 and seven in the TCGA dataset that had received prior treatment. The unfiltered 155-gene set showed clinically relevant clustering of human primary tumors into subgroups with different outcomes, even though it probably contained gene expression events that were specific to our cell lines. Therefore, we used the GSE2109 dataset to filter out genes that behaved discordantly between our experimental model and the clinical samples. This step reduced the number of genes to 50, yielding a classifier (RMS50 for Renal cancer Metastasis Signature) that provided a tight correlation with clinical outcome in both the TCGA and GSE3538 cohorts ( Fig. 1h and Supplementary Fig. 3d-g ).
Altered VHL-HIF response in metastatic ccRCC cells One of the most highly overexpressed genes in the metastatic cells was CXCR4 (52-fold; Supplementary Table 1), which was of interest for two reasons. First, CXCR4 expression correlates with poor prognosis and metastasis in ccRCC 6, 22, 26 . Second, CXCR4 is induced by VHL loss 6, 27 . We confirmed the higher expression of CXCR4 in the metastatic cells by quantitative RT-PCR (qRT-PCR) and also showed that this induction was strongly dependent on VHL loss (Fig. 2a) . Furthermore, CXCR4 mRNA levels were associated with disease progression in a cohort comprising mainly early stage ccRCC samples collected at our institution (Fig. 2b) . The expression of VEGFA (vascular endothelial growth factor A) and ADM (adrenomedullin), two known VHL-HIF target genes 28 , was similar in 786-O and 786-M1A cells (Fig. 2c) . Also, there were no differences in VHL mutation status (data not shown) or HIF2-α protein expression ( Supplementary  Fig. 4a ) between these cell lines. These findings suggest that clonal derivatives of a single VHL-mutant cell can have substantial variation in the VHL-HIF pathway transcriptional output and that this variation is associated with different tumor phenotypes.
To determine whether this alteration in the VHL-HIF signal output included genes other than CXCR4, we performed gene expression profiling. Of the 137 genes that were significantly regulated by VHL in the 786-M1A cells (Supplementary Table 2 ), 37 were also present in the 155-gene set (Fig. 2d) . This overlap was more than what would be expected by chance alone and included both upregulated and downregulated genes. Also, these 37 overlapping genes were significantly (P = 0.0076) enriched in two of the four possible categories: they were induced by VHL loss and upregulated in metastatic cells or repressed by VHL loss and downregulated in metastatic cells (Supplementary Fig. 4b ).
As HIFs are primarily transcriptional activators 29 , we focused on the 12 genes that were both upregulated by VHL loss and had higher expression in the metastatic cells. To avoid possible confounding effects caused by tumors in which the HIF pathway was not activated, we analyzed the expression of these VHL-regulated genes in a set of VHL-mutant primary ccRCC specimens 30 . VHL mutation status was not associated with RMS50 status (Supplementary Fig. 4c ), but a subset of metastasis-associated VHL-HIF target genes, namely CXCR4, CYTIP, SLAMF8 (SLAM family member 8), CXCR7 and LTBP1 (latent transforming growth factor β binding protein 1) had significantly (P < 0.05) higher expression in RMS50-positive VHLnegative tumors (Supplementary Fig. 5a ). The expression of other genes, such as VEGFA and ADM, showed no such difference ( Supplementary  Fig. 5b) . We confirmed the expression of these genes by qRT-PCR in our cell-line model (Fig. 2e) . The expression of these genes was dependent on HIF2-α (Fig. 2f) . Analysis of protein levels Supplementary Fig. 5c,d) .
To determine the generality of these findings, we used two additional VHL-mutant human ccRCC cell-line systems. One of them (RFX-631) spontaneously formed robust lung metastasis with a mixed epithelioid and sarcomatoid histology (Supplementary Fig. 6a ). The other cell line (OS-RC-2) was more indolent and gave rise to metastatic OS-LM1 variants after in vivo selection ( Supplementary  Fig. 6b-d) . The OS-LM1 metastatic nodules were of the classic clear cell morphology, with some regions containing cells with eosinophilic cytoplasm (Supplementary Fig. 6e ). The expression of all five genes (CXCR4, CYTIP, SLAMF8, CXCR7 and LTBP1) was dependent on VHL loss in at least one of these two model systems, and CXCR4, CYTIP and LTBP1 expression was reduced after VHL reintroduction in both RFX-631 and OS-LM1 cells (Fig. 2g,h) . CXCR4, CYTIP, LTBP1 and SLAMF8 all showed varying degrees of overexpression in OS-LM1 cells when compared to the parental OS-RC-2 cells ( Supplementary  Fig. 6f ), confirming that their expression was more generally selected for in cells with metastatic potential. Therefore, the VHL-HIF pathway drives not only ccRCC initiation but also the expression of several genes that are associated with ccRCC metastasis (Fig. 2i) .
Expanded HIF signal output activates mediators of metastasis Reintroduction of VHL strongly inhibited 786-M1A lung-colonizing activity (Fig. 3a) . Among the VHL-HIF-dependent genes that were associated with metastasis in our model systems, CXCR4 and CXCR7 encode G protein-coupled receptors for the chemokine CXCL12 (refs. 1,17,18) . CYTIP encodes a ~40 kDa intracellular protein that can enhance AP1 transcriptional responses 31 , modulate cell adhesion and migration [32] [33] [34] , and support stem-cell fitness 32 . LTBP1 encodes a large extracellular protein that regulates transforming growth factor β (TGF-β) activation 35 . SLAMF8 encodes a cell-surface receptor that is normally expressed in activated macrophages. To prioritize our functional analysis, we focused on CXCR4, CYTIP and LTBP1, genes that were consistently associated with metastasis across all cell-line systems (Fig. 2a,e,g,h) . LTBP1 was not essential for lung metastasis in the 786 model ( Supplementary Fig. 7a,b) , possibly because of compensation by LTBP4 (Supplementary Table 1) or other LTBP family members, whereas knockdown of CYTIP or CXCR4 inhibited the lung-colonizing activity of 786-M1A cells by tenfold ( Fig. 3b and Supplementary  Fig. 8a,b) . Combinatorial knockdown of both genes further reduced the lung metastatic burden (Fig. 3b) . Both CYTIP and CXCR4 complementary DNA (cDNA) constructs also enhanced the metastatic potential of 786-O cells ( Fig. 3c and Supplementary Fig. 8c ). Combinatorial knockdown of CYTIP and CXCR4 strongly inhibited OS-LM1 lung colonization as well ( Fig. 3d and Supplementary Fig. 8d ).
To determine the cellular mechanisms through which CXCR4 and CYTIP contributed to metastasis, we tested their effects on phenotypes relevant to metastasis in vitro. As previously reported 6 , CXCR4 mediated CXCL12-directed chemotactic migration in metastatic 786-M1A cells, with associated changes in Erk phosphorylation status ( Fig. 3e and Supplementary Fig. 9a,b) . The CXCR4 inhibitor AMD3100 blocked the chemotactic phenotype in vitro (Fig. 3e) and reduced metastasis formation in vivo (Fig. 3f) . Relative mRNA level
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Relative mRNA level Fig. 9c ). However, CYTIP knockdown also inhibited bone metastasis (Fig. 3g) . As extravasation through sinusoid capillaries in the bone marrow is not thought to be rate limiting for bone metastasis, we reasoned that CYTIP might support the survival of disseminating cancer cells. Indeed, CYTIP knockdown significantly reduced cancer-cell viability in the presence of the cell-death cytokine TRAIL (Fig. 3h) .
DNA demethylation allows CYTIP expression in metastatic ccRCC
We used the two functionally validated target genes, CXCR4 and CYTIP, to investigate the basis of the altered VHL-HIF response. We found little evidence for genomic amplification, altered mRNA stability or increased promoter activity as the explanation for the increased expression of these genes ( Supplementary Fig. 10a-c) . We therefore asked whether epigenetic changes in transcriptional accessibility of these loci 36 could explain our observations. Indeed, the promoter regions of CXCR4 and CYTIP, but not that of VEGFA, were more sensitive to DNase I in the metastatic cells ( Supplementary  Fig. 11a,b) . This difference remained after enforced expression of VHL (Supplementary Fig. 11b) , showing that DNase sensitivity was not simply associated with transcriptional activity.
Mutations in epigenetic regulators make these genes attractive candidates as mediators of epigenetic remodeling in ccRCC 30, 37 . In our analysis, RMS50 positivity was not associated exclusively with PBRM1-, SETD2-or JARID1C-mutant tumors (Supplementary Fig. 12 ), and these genes showed no mutational differences between our parental and metastatic cells. Also, inhibition of PBRM1, JARID1C or SETD2 did not result in consistent changes in CXCR4 expression (Supplementary Fig. 13 ).
Genome-wide assessment of DNA methylation revealed that in 786-O cells, genes that were overexpressed in the metastatic cells had higher levels of DNA methylation near the transcription start site (TSS) when compared to unchanged genes or random genomic loci (Supplementary Fig. 14a ). This methylation was reduced in the metastatic cells to the level of unchanged genes. The downregulated genes showed methylation levels comparable to those of the unchanged genes both in the parental and metastatic cells ( Supplementary  Fig. 14b ). Among genomic regions with the greatest DNA methylation difference between the metastatic and nonmetastatic cells, 756 out of 772 regions (98%, P < 1.0 × 10 −10 ) had lower methylation in the metastatic cells (Fig. 4a) . Of the 756 regions with reduced DNA methylation, 18 were associated with upregulated genes in the 155-gene set (P = 5.6 × 10 −7 ). However, the majority of the genes were not associated with transcriptional changes. CYTIP showed reduced methylation near the TSS, whereas CXCR4 showed low levels of DNA methylation across the whole gene locus and no difference between the cell lines ( Fig. 4b and Supplementary Fig. 15a ). We confirmed these results with targeted analysis of the most highly induced RMS50 genes (Supplementary Fig. 15b) .
To evaluate the role of DNA methylation in CYTIP expression, we treated 786-O cells with the DNA methyltransferase inhibitor 5′-aza-deoxycytidine (5DC). This led to DNA demethylation (Supplementary Fig. 15c ) and robust expression of CYTIP but not CXCR4, ADM or VEGFA (Fig. 4c) . CYTIP induction was dependent on VHL inactivation (Fig. 4c) , and it remained high 2 weeks after 5DC treatment (Supplementary Fig. 15d ). Concordantly, we detected little DNA methylation at the CXCR4 promoter in an analysis of 78 untreated human primary ccRCC specimens (Fig. 4d) , whereas the CYTIP promoter contained abundant DNA methylation in these samples (Fig. 4e) . We found a significant inverse correlation between tumor grade and stage with CYTIP methylation (Fig. 4e and  Supplementary Fig. 16 ). Low levels of CYTIP methylation correlated with poor disease outcome (Fig. 4f) . Thus, changes in CYTIP DNA npg methylation were associated with aggressive tumor phenotypes both in our experimental model and clinically.
Loss of H3K27me3 repressive mark at the CXCR4 locus The involvement of DNA methylation in CYTIP but not CXCR4 regulation implied that multiple mechanisms of VHL-HIF output amplification are co-selected during ccRCC progression. The CXCR4 locus in stem cells is marked by a bivalent histone H3 modification with trimethylated Lys4 and Lys27 (H3K4me3 and H3K27me3, respectively) 38 . H3K4me3 is generally a mark of transcriptionally active genes, and H3K27me3 is a mark of repressed genes 39 . Chromatin immunoprecipitation sequencing (ChIP-seq) experiments revealed that, in general, 786-M1A cells contained more H3K4me3 near upregulated genes in the 155-gene set when compared to the parental cells, whereas the opposite was true for the downregulated genes ( Supplementary Fig. 17a ). H3K27me3 followed an inverse pattern, where genes with higher expression in the metastatic cells showed less H3K27me3 and vice versa (Supplementary Fig. 17b ) relative to the control experiment with IgG ( Supplementary Fig. 17c ). In individual genes, H3K4me3 for the most part followed the pattern expected for transcriptionally active genes, as shown for CXCR4 and CYTIP (Fig. 5a ). For H3K27me3, however, only a few genes, including CXCR4, drove the observed global difference between the cell lines (Fig. 5b) . The majority of the genes, including CYTIP (Fig. 5b) , contained amounts of H3K27me3 that were comparable to those of the negative IgG control (Supplementary Fig. 17d ).
We next identified genomic loci that showed the greatest difference in H3K4me3 and H3K27me3 enrichment between the parental and metastatic cells regardless of their expression pattern. For H3K4me3, this revealed a uniform distribution of both higher and lower enrichment in the metastatic cells (Supplementary Fig. 18a ). In contrast, for H3K27me3, the distribution was strongly skewed, with the most differentially enriched regions having a lower amount of H3K27me3 in the metastatic cells (Supplementary Fig. 18b ). Among the 155 metastasis-associated genes, we found a strong correlation between changes in the amount of H3K4me3 and gene expression, especially for the genes that were activated in the metastatic cells Fig. 18c,d ). For H3K27me3, however, we found no statistically significant overlap ( Supplementary Fig. 18c) ; the only shared gene between the 74 most differentially changed regions and the genes upregulated in metastatic cells was CXCR4. Hence, the majority of H3K27me3 demethylation events do not automatically lead to transcriptional activation.
We confirmed these ChIP-seq results by ChIP-qPCR and tested the effects of VHL reintroduction on the histone modification status of CXCR4 and CYTIP. Whereas the high amounts of H3K4me3 were strongly dependent on VHL-HIF pathway activity (Fig. 5c) , the amount of H3K27me3 remained unchanged by reintroduction of VHL (Fig. 5d) .
Loss of PRC2-mediated repression of CXCR4 in metastatic ccRCC
H3K27me3 is a hallmark of gene repression by PRC2 (ref. 40) . Among the genes encoding the core PRC2 subunits 40 (EED, EZH1, EZH2, SUZ12, RBBP4 and RBBP7), SUZ12 mRNA levels were downregulated in the metastatic cells (P = 0.009), although the fold change in the 786-O system did not qualify for the 155-gene set. The metastatic cells had lower expression of SUZ12 protein, whereas both the parental and metastatic cells had similar expression of EZH2 (Fig. 6a) . ChIP-qPCR experiments reveled that SUZ12 binding was reduced at the CXCR4 promoter of 786-M1A cells (Fig. 6b) . Low SUZ12 expression also correlated with ccRCC progression (Fig. 6c) . The RMS50-positive tumors in the TCGA cohort had both higher expression of CXCR4 (P = 5.2 × 10 −7 ) and lower expression of SUZ12 (P = 8.3 × 10 −9 ).
Knockdown of SUZ12 in the 786-O cells led to a reduction in H3K27me3 at the CXCR4 promoter ( Fig. 6d and Supplementary  Fig. 19a ) and a proportional increase in CXCR4 expression (Fig. 6e) . The SUZ12 knockdown cells had an enhanced metastatic phenotype in vivo (Fig. 6f) . CXCR4 expression was also increased with a reduction in the amount of H3K27me3 when EZH1 and EZH2 were knocked down together but not when each was knocked down individually ( Fig. 6g and Supplementary Fig. 19b,d) , which is in line with previous reports showing functional redundancy of EZH1 and EZH2 (refs. 41-43) .
We then analyzed the transcriptome-wide effects of 5DC and knockdown of SUZ12 in the 786-O system ( Supplementary  Fig. 20a,b and Supplementary Tables 3 and 4) . This revealed a substantial overlap between the 155-gene set and the genes regulated by DNA methylation or SUZ12. However, the majority of the gene expression changes caused by 5DC or SUZ12 knockdown were not part of the 155-gene set, indicating the involvement of additional factors imposing selectivity.
DISCUSSION
Here we show that repressive chromatin modifications and DNA methylation restrict the expression of metastasis-associated VHL-HIF target genes and liberation from these constraints mediates ccRCC metastasis. The transcriptional output of the VHL-HIF pathway thus evolves during ccRCC progression to further enhance the metastatic potential of the pathway (Fig. 6h) . These findings provide insights into the interplay between genetic and epigenetic mechanisms in the selection of metastatic traits.
The role of the VHL-HIF pathway in ccRCC initiation is well established 5 , and the VHL-HIF target CXCR4 has been proposed to drive ccRCC metastasis 6 . Clinical data suggest, however, that VHL-HIF activation does not automatically lead to the activation of metastasis genes 21 . Our data show that a metastatic subprogram of the VHL-HIF pathway is activated only in a subpopulation of cancer cells in renal tumors. We find that CXCR4 and CYTIP are important mediators of the metastatic phenotype driven by the altered VHL-HIF response. CXCR4 has previously been implicated in the metastatic progression of other cancers 1, 17, 18 , and CXCL12, the ligand for CXCR4 and CXCR7, can attract ccRCC cells as well 6 , results that we confirmed in our model system. We identified additional genes that follow similar expression patterns, one of which is the intracellular . Shown is the normalized bioluminescence photon flux of the lungs at day 68. n = 7-10 mice. The P values shown were calculated using two-tailed Wilcoxon rank-sum test. (g) CXCR4 expression measured by qRT-PCR analysis after combinatorial knockdown of both EZH1 and EZH2 with two separate shRNAs, one for EZH1 and one for EZH2 (EZH1/2sh). Error bars represent the 95% confidence intervals based on multiple PCR reactions. (h) VHL loss initiates renal tumorigenesis by stabilizing HIF2-α, which leads to the activation of several target genes, such as VEGFA. At this stage, many potential VHL-HIF target genes are only weakly expressed because of various inhibitory mechanisms (for example, DNA methylation and PRC2-dependent repression). Changes in the epigenetic landscape can allow hyperinduction of VHL-HIF target genes. If these genes are beneficial to the tumor (for example, CXCR4 and CYTIP), they will drive ccRCC progression and get selected for. npg signal modulator CYTIP. Our work establishes a new role for CYTIP in supporting survival under stressed conditions and points to additional HIF target genes for future studies.
The pathways that drive metastasis are often considered separate from tumor-initiating functions 4 . In the case of ccRCC, the major tumorinitiating pathway is also exploited for the acquisition of metastatic traits. The central role of the VHL-HIF pathway as a gatekeeper for renal tumorigenesis makes ccRCC an ideal model system for studying the connection between metastatic phenotypes and tumor-initiating mechanisms. It is possible that the phenotypes of other tumor-initiating pathways can also expand to cover metastatic functions. The concept emerging from this work could therefore have implications for our understanding of the evolution of metastatic traits more generally.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data have been deposited at GEO (www. ncbi.nlm.nih.gov/geo/) under accession code GSE32299.
Note: Supplementary information is available in the online version of the paper.
Overexpression and RNA interference (RNAi). For CXCR4 and CYTIP cDNA overexpression, we used the pBABE-puro retroviral expression vector. The pBABE-HA-VHL plasmid was generated by the Kaelin lab 44 and obtained from Addgene (plasmid 19234). We used empty pBABE vector as the control. Virus production in the GPG29 packaging cells followed published protocols 45 . The virus-containing supernatant was then concentrated by ultracentrifugation, resuspended in RPMI medium and used for infection in the presence of polybrene (8 µg ml −1 ). Puromycin selection started the next day (4 µg ml −1 ). Similarly, we used a triple modality retroviral reporter plasmid to stably label cells for bioluminescence imaging 46 , followed by selection of GFP + cells by fluorescence-activated cell sorting (FACS).
For RNAi-mediated gene silencing, we obtained clones and the corresponding empty vectors from Open Biosystems. For EZH1, we used DNA oligonucleotides for the cloning of miR-30-based shRNA constructs into the pGIPZ and pHAGE-puro vectors 47 . The clone numbers and oligonucleotide sequences are listed in Supplementary Table 5 .
For HIF2-α knockdown, we produced retrovirus as described above. For lentivirus production, we infected HEK 293T cells with the shRNA-containing plasmid together with the packaging plasmids psPAX2 and pMD2.G using Lipofectamine 2000 (Invitrogen). We harvested the virus 48 h after transfection and then filtered and used it to infect target cells in the presence of polybrene (8 µg ml −1 ). Puromycin selection started the next day (4 µg ml −1 ). We used the corresponding empty vector as a control (pLKO.1 for CYTIP and pGIPZ for CXCR4, LTBP1 and SUZ12). For combination knockdown, we added two different viral supernatants into the same transduction mix. Correspondingly, the control for combination knockdown experiments contained both pLKO.1 and pGIPZ empty vectors.
Mouse studies and isolation of metastatic cells. We performed all animal experiments in accordance with a protocol approved by MSKCC Institutional Animal Care and Use Committee. For in vivo selection, we inoculated cells (400,000) resuspended in 100 µl of PBS into the lateral tail vein of 5-to 7-week-old male nonobese diabetic severe combined immunodeficient (NOD/SCID) mice. We monitored tumor growth by bioluminescence imaging of anesthetized mice (100 mg per kg body weight ketamine and 10 mg per kg body weight xylazine) by retro-orbitally injecting d-luciferin (150 mg per kg body weight) and imaging with the IVIS Spectrum Xenogen machine (Caliper Life Sciences). When a growing signal was observed for several weeks, we harvested the lungs, dissected tumor nodules from the lungs, minced them and placed them in RPMI supplemented with 0.125% collagenase III and 0.1% hyaluronidase. Samples were then gently rocked in 37 °C for 3-4 h, briefly centrifuged and resuspended in 0.25% trypsin for 10 min with vortexing every 2 min. We then centrifuged cells and plated them in RPMI medium. After reaching confluency, GFP + cells were sorted by FACS and reinjected into mice. For the comparison of parental and metastatic cells in the lung colonization assays, we injected 150,000 cells (except for 786-M1B cells, for which three mice were injected with 150,000 cells and four mice were injected with 400,000 cells). In all subsequent lung colonization assays, we used 150,000 cells. For bone and brain metastasis assays, we injected cells (100,000) into the left vetricle of 5-to 7-week-old anesthetized athymic male nude mice. We monitored metastatic colonization by bioluminescence and X-ray imaging. For orthotopic renal subcapsular injections, we mixed cells with Matrigel. Incisions were made into the left flank of anesthetized mice, and the left kidneys were exposed. Ten microliters of Matrigel containing 15,000 cells were carefully injected under the renal capsule, and the incision was sutured. We confirmed the injections by bioluminescent imaging. We confirmed brain metastases and lung metastasis after orthotopic injections by ex vivo imaging. For drug experiments, we purchased AMD3100 from Sigma and injected the drug intraperitoneally twice daily (2.5 mg per kg body weight).
Histological analysis and immunostaining. After being euthanized, mice were perfused with 4% paraformaldehyde. Target organs were collected and fixed overnight in 4% paraformaldehyde, washed, embedded in paraffin and sectioned. H&E staining was performed by standard methods. The MSKCC Molecular Cytology Core Facility performed immunostaining for GFP (Abcam) according to standard methods.
In vitro assays. For proliferation assays, we plated cells (500 per well) on 96-well plates and measured growth using the resazurin reagent (R&D Systems) according to the manufacturer's instructions. We read the signal using a plate reader at each time point in eight independent wells. For cell migration assays, we starved cells overnight (0.2% FBS-containing medium). The next day, we plated 50,000 cells on FluoroBlok cell culture inserts (BD Falcon) with 8-µm pores placed in control, recombinant human CXCL12-containing (R&D) or CXCL12 + AMD3100-containing (Sigma) medium. Fourteen hours later, the cells were fixed and stained with DAPI. Migration to the basolateral side of the membrane (nuclei stained with DAPI) was quantified using ImageJ software (three random fields for replicate wells) from images obtained by an AMG Evos FL microscope. We quantified cell survival by the CellTiter-Glo cell viability assay (Promega). We plated cells (100,000) on six-well plates with no serum, adding recombinant human TRAIL (PeproTech) the next day and measuring cell survival 2 d later.
DNA sequencing. The MSKCC DNA sequencing core facility sequenced VHL by capillary sequencing using previously published primer sequences 48 . SETD2, JARID1C, UTX and PBRM1 capillary sequencing was performed in the MSKCC Beene Translational Oncology Core Facility. mRNA and protein detection. We extracted total RNA using PrepEase RNA spin kit (USB). RNA (1 µg) was used to generate cDNA with the Transcriptor First Strand cDNA Synthesis Kit (Roche). For qPCR, we used predesigned TaqMan gene expression assays (Applied Biosystems) and the ABI 7900HT Fast Real-Time PCR System. TBP served as a housekeeping control gene in the analysis performed using the SDS2. Clinical ccRCC samples. After informed consent was obtained, we collected a set of 91 surgically removed primary ccRCC specimens at our institution according to a protocol approved by the MSKCC Institutional Review Board and Human Biospecimen Utilization Committee. Samples were snap frozen, and DNA and RNA were extracted by standard methods. mRNA expression analysis of clinical ccRCC samples. Direct assessment of CXCR4 mRNA expression was performed by the nCounter Analysis System (NanoString Technologies) according to the manufacturer's recommendations. The method is based on a solution-phase hybridization protocol that allows direct detection of target mRNA molecules in small amounts of input RNA. After data preprocessing and background correction, each sample was normalized for RNA loading using the ribosomal genes RPL13A, RPL24, RPL27 and RPS20. All 91 RNA samples passed the initial data quality control criteria.
DNA methylation analysis. The effects of DNA methylation on gene expression were studied by treating cells with 5DC followed by qRT-PCR. A concentration of 100 nM was used in all experiments. The MSKCC Beene Translational Oncology Core Facility carried out the analysis of CpG methylation using the EpiTyper system (Sequenom), which performs quantitative analysis of DNA methylation using base-specific cleavage of bisulfite-treated DNA and matrixassisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. One microgram of DNA was subjected to bisulfite treatment using the EZ-96 DNA methylation Kit following the manufacturer's instructions npg (Zymo Research). Specific PCR primers with T7-promoter tags were designed using the EpiDesigner software (www.epidesigner.com). After PCR and shrimp alkaline phosphatase (SAP) treatment, in vitro transcription and T cleavage were carried out using the MassCleave kit (Sequenom). The EpiTyper reaction product was then loaded onto a SpectroCHIP II array (Sequenom) and analyzed using a Bruker Biflex III MALDI-TOF mass spectrometer (SpectroREADER, Sequenom). Results were analyzed using the EpiTyper Analyzer software and manually inspected for spectra quality and peak quantification. Of the clinical samples, 78 passed the quality control criteria and were used for further analysis.
DNase I sensitivity assays. We assessed chromatin accessibility as a function of DNase I sensitivity following previously published protocols with modifications 49, 50 . Cells were trypsinized and counted, washed once with PBS and resuspended in 500 µl of ice-cold RSB buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl and 3 mM MgCl 2 ). Cells were lysed by slowly adding 8 ml of cold lysis buffer (RSB supplemented with 0.1% IGEPAL CA-630) and incubated on ice for 10 min. Nuclei were pelleted by centrifuging for 5 min at 500g, washed once with 5 ml of cold RSB, resuspended in DNase I reaction buffer (Roche) at a ~7 × 10 6 ml −1 concentration and aliquoted into multiple tubes. Treatment with recombinant DNase I was carried out at 37 °C for 20 min, and the reaction was stopped by adding an equal volume of stop buffer (0.1 M NaCl, 0.1% (w/v) SDS, 50 mM Tris-HCl (pH 8.0) and 100 nM EDTA). Samples were then treated with proteinase K overnight, and DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen). The DNase I digestion was first optimized by testing several different concentrations (10-200 U per 180 µl reaction). For the final experiments, we performed three or four DNase treatments with the same concentration. We quantified DNA by PCR using the SYBR Green Mix (Thermo Scientific) and ABI 7900HT Fast Real-Time PCR System absolute quantification method. DNase-insensitive control loci (chromosome 15 at 22 Mb and chromosome 17 at 17 Mb) that were randomly chosen on the basis of DNase data from multiple cell lines available at the UCSC genome browser (http://genome. ucsc.edu/) and empirically validated as regions showing minimal sensitivity to DNase when compared to nontreated controls served as normalization controls. The PCR primers used are listed in Supplementary Table 6. 
